Suppr超能文献

多组学整合分析揭示了在3P医学框架下人类无功能垂体神经内分泌肿瘤中的分子网络改变。

Muti-omics integration analysis revealed molecular network alterations in human nonfunctional pituitary neuroendocrine tumors in the framework of 3P medicine.

作者信息

Wen Siqi, Li Chunling, Zhan Xianquan

机构信息

Shandong Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, 440 Jiyan Road, Jinan, Shandong 250117 People's Republic of China.

Medical Science and Technology Innovation Center, Shandong First Medical University, Jinan, 6699 Qingdao Road, Jinan, Shandong 250117 People's Republic of China.

出版信息

EPMA J. 2022 Feb 17;13(1):9-37. doi: 10.1007/s13167-022-00274-5. eCollection 2022 Mar.

Abstract

Nonfuctional pituitary neuroendocrine tumor (NF-PitNET) is highly heterogeneous and generally considered a common intracranial tumor. A series of molecules are involved in NF-PitNET pathogenesis that alter in multiple levels of genome, transcriptome, proteome, and metabolome, and those molecules mutually interact to form dynamically associated molecular-network systems. This article reviewed signaling pathway alterations in NF-PitNET based on the analyses of the genome, transcriptome, proteome, and metabolome, and emphasized signaling pathway network alterations based on the integrative omics, including calcium signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway, PI3K/AKT signaling pathway, MAPK (mitogen-activated protein kinase) signaling pathway, oxidative stress response, mitochondrial dysfunction, and cell cycle dysregulation, and those signaling pathway networks are important for NF-PitNET formation and progression. Especially, this review article emphasized the altered signaling pathways and their key molecules related to NF-PitNET invasiveness and aggressiveness that are challenging clinical problems. Furthermore, the currently used medication and potential therapeutic agents that target these important signaling pathway networks are also summarized. These signaling pathway network changes offer important resources for insights into molecular mechanisms, discovery of effective biomarkers, and therapeutic targets for patient stratification, predictive diagnosis, prognostic assessment, and targeted therapy of NF-PitNET.

摘要

无功能垂体神经内分泌肿瘤(NF-PitNET)具有高度异质性,通常被认为是一种常见的颅内肿瘤。一系列分子参与了NF-PitNET的发病机制,这些分子在基因组、转录组、蛋白质组和代谢组的多个层面发生改变,并且这些分子相互作用形成动态关联的分子网络系统。本文基于对基因组、转录组、蛋白质组和代谢组的分析,综述了NF-PitNET中的信号通路改变,并强调了基于整合组学的信号通路网络改变,包括钙信号通路、cGMP-PKG信号通路、mTOR信号通路、PI3K/AKT信号通路、MAPK(丝裂原活化蛋白激酶)信号通路、氧化应激反应、线粒体功能障碍和细胞周期失调,而这些信号通路网络对NF-PitNET的形成和进展至关重要。特别是,这篇综述文章强调了与NF-PitNET侵袭性和侵袭性相关的改变的信号通路及其关键分子,这些都是具有挑战性的临床问题。此外,还总结了目前针对这些重要信号通路网络所使用的药物和潜在治疗药物。这些信号通路网络变化为深入了解分子机制、发现有效的生物标志物以及为NF-PitNET的患者分层、预测诊断、预后评估和靶向治疗提供治疗靶点提供了重要资源。

相似文献

2
Quantitative Acetylomics Revealed Acetylation-Mediated Molecular Pathway Network Changes in Human Nonfunctional Pituitary Neuroendocrine Tumors.
Front Endocrinol (Lausanne). 2021 Oct 12;12:753606. doi: 10.3389/fendo.2021.753606. eCollection 2021.
5
Molecular characterization of epithelial-mesenchymal transition and medical treatment related-genes in non-functioning pituitary neuroendocrine tumors.
Front Endocrinol (Lausanne). 2023 Mar 22;14:1129213. doi: 10.3389/fendo.2023.1129213. eCollection 2023.
6
Multiomics-Based Signaling Pathway Network Alterations in Human Non-functional Pituitary Adenomas.
Front Endocrinol (Lausanne). 2019 Dec 17;10:835. doi: 10.3389/fendo.2019.00835. eCollection 2019.
8
SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth Targeting VEGFA.
Front Endocrinol (Lausanne). 2020 Dec 9;11:566761. doi: 10.3389/fendo.2020.566761. eCollection 2020.
10
Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies.
EPMA J. 2021 Jun 26;12(3):383-401. doi: 10.1007/s13167-021-00246-1. eCollection 2021 Sep.

引用本文的文献

2
The role of protein acetylation in carcinogenesis and targeted drug discovery.
Front Endocrinol (Lausanne). 2022 Sep 12;13:972312. doi: 10.3389/fendo.2022.972312. eCollection 2022.
3
Cancer glycomics offers potential biomarkers and therapeutic targets in the framework of 3P medicine.
Front Endocrinol (Lausanne). 2022 Aug 22;13:970489. doi: 10.3389/fendo.2022.970489. eCollection 2022.
5
Advances in Plant Metabolomics and Its Applications in Stress and Single-Cell Biology.
Int J Mol Sci. 2022 Jun 23;23(13):6985. doi: 10.3390/ijms23136985.

本文引用的文献

1
Quantitative Acetylomics Revealed Acetylation-Mediated Molecular Pathway Network Changes in Human Nonfunctional Pituitary Neuroendocrine Tumors.
Front Endocrinol (Lausanne). 2021 Oct 12;12:753606. doi: 10.3389/fendo.2021.753606. eCollection 2021.
3
The use of mass spectrometry in a proteome-centered multiomics study of human pituitary adenomas.
Mass Spectrom Rev. 2022 Nov;41(6):964-1013. doi: 10.1002/mas.21710. Epub 2021 Jun 9.
4
Targeting Nrf2-Mediated Oxidative Stress Response Signaling Pathways as New Therapeutic Strategy for Pituitary Adenomas.
Front Pharmacol. 2021 Mar 24;12:565748. doi: 10.3389/fphar.2021.565748. eCollection 2021.
6
7
Integrated multi-omics profiling of nonfunctioning pituitary adenomas.
Pituitary. 2021 Jun;24(3):312-325. doi: 10.1007/s11102-020-01109-0. Epub 2020 Nov 18.
8
Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.
Int J Med Sci. 2020 Oct 23;17(18):3174-3189. doi: 10.7150/ijms.51176. eCollection 2020.
9
Identification of driver genes and key pathways of non-functional pituitary adenomas predicts the therapeutic effect of STO-609.
PLoS One. 2020 Oct 29;15(10):e0240230. doi: 10.1371/journal.pone.0240230. eCollection 2020.
10
UPLC-MS/MS-based Lipidomic Profiles Revealed Aberrant Lipids Associated with Invasiveness of Silent Corticotroph Adenoma.
J Clin Endocrinol Metab. 2021 Jan 1;106(1):e273-e287. doi: 10.1210/clinem/dgaa708.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验